Lymphoma
Conditions
Keywords
T-Cell Lymphoma, Lymphoma, Campath-1H, Allogenic Transplantation, Stem Cell Transplant, Alemtuzumab
Brief summary
Primary Objectives: 1. To evaluate the role of autologous and allogenic stem cell transplantation with Campath-1H for patients with peripheral T-cell lymphoma (PTCL). 2. To examine the impact of in-vivo purging with Campath -1H pre-autologous stem transplantation for patients with PTCL. 3. To evaluate the impact of soluble CD52 upon in-vivo purging with Campath-1H. 4. To evaluate the role of Campath -1H in the treatment minimal residual disease after autologous transplantation for PTCL.
Detailed description
Campath is a drug that can specifically attack some types of T-cell lymphoma cells. Before the study begins, you will have a physical exam, including blood (about 2 tablespoons) and urine tests. Women who are able to have children must have a negative blood pregnancy test. Bone marrow samples will be taken. To collect a bone marrow sample, an area of the hip or chest bone is numbed with anaesthetic and a small amount of bone marrow is withdrawn through a large needle. Patients will have a chest x-ray, an EKG (test to measure the electrical activity of the heart), and tests of lung function. Patients whose disease affects the stomach or intestines may have biopsies of these areas. Treatment will be given in the hospital at M. D. Anderson. You will need to stay in the hospital for about 3 to 4 weeks. A central venous catheter (plastic tube) will be placed into the large chest vein. The catheter will be left in place throughout treatment. In order to collect stem cells, G-CSF and GM-CSF will be injected under the skin. This will be done twice a day until the collection of stem cells is complete. You will receive Campath -1H through the catheter on Days 1, 2, 3, and 10 of chemotherapy treatment. The stem cells will be collected from you starting about 10 to 14 days after chemotherapy is given. The collection process is called apheresis. Blood is removed from the your body and the stem cells are frozen for storage. Stem cell collection takes about 3 hours. Between 3 and 5 sessions may be needed to collect enough stem cells. Sessions will be done once a day. After stem cells are collected, you will receive high dose Carmustine over 1 hour on Day 1. You will receive cytarabine and etoposide twice a day on Days 2 through 5 and melphalan on Day 6. One day after finishing the chemotherapy, the stem cells that were collected earlier will be infused back into you over about 30 minutes. G-CSF and GM-CSF will be injected until your white blood cell counts returns to normal. Blood tests (1-2 tablespoons), urine tests, bone marrow sampling, and x-rays will be done as needed to track the effects of the transplant. You will have transfusions of blood and platelets as needed. Blood tests (1-2 tablespoons) will be done daily while you are in the hospital. You might have to stay in the Houston area for 2 to 4 weeks after the transplant. After that, you will need to return to Houston every 3 months for the first year, then every 6 months for 5 years. Three months after the transplant, bone marrow exams and other tests will be done. If you show evidence of disease, you will receive another cycle of Campath -1H three times a week for 4-12 weeks. Patients will be taken off study if the disease gets worse or intolerable side effects occur. This is an investigational study. The FDA has approved the drugs used in this study. Their use together in this study is investigational. About 30 patients will take part in this study. All will be enrolled at M. D. Anderson. Nonmyeloablative Allogeneic Transplantation with Campath-1H for T-cell Lymphoma: Campath is a drug that can specifically attack some types of T-cell lymphoma cells. In addition, it weakens the immune system, therefore helping to prevent the rejection of donor marrow or stem cells. TBI is designed to damage the DNA (the genetic material of cells) of cancer cells, which may kill the cancer cells. Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. This may cause the cancer cells to die. Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may increase the likelihood of the cells dying. Before the study begins, you will have a physical exam, including blood (about 1-2 tablespoons) and urine tests. Women who are able to have children must have a negative blood pregnancy test. Bone marrow samples will be taken. To collect a bone marrow sample, an area of the hip or chest bone is numbed with anaesthetic and a small amount of bone marrow is withdrawn through a large needle. You will have a chest x-ray, CT scans, an EKG (test to measure the electrical activity of the heart), and tests of lung function. Blood tests (1-2 tablespoons), urine tests, bone marrow sampling, and x-rays will be done as needed to track the effects of the transplant. Patients will have transfusions of blood and platelets as needed. Blood tests (1-2 tablespoons) will be done daily while you are in the hospital. Campath-1 H will be injected into your vein. This will be done 3 days in a row (Days 1 to 3). The drugs diphenhydramine (Benadryl), acetaminophen (Tylenol) and hydrocortisone will be given in to decrease the risk of or ease side effects. You will also receive fludarabine and cyclophosphamide daily for 3 days. They will be given starting day of Campath -1H. All of the chemotherapy drugs will be given through a catheter (plastic tube) that extends into the large chest vein. The catheter will be left in place throughout treatment. After completion of chemotherapy, you will receive TBI, and later on the same day, blood stem cells from a donor will be given through the catheter. G-CSF and GM-CSF, growth factors that promote the production of blood cells, will be injected under the skin once a day until the neutrophil counts recover in the blood. Tacrolimus will be infused through the vein, starting 2 days before transplant to decrease the risk of graft-versus-host disease. It will be changed to pills after you are discharged from the hospital. For the same purpose, methotrexate will also be given through the vein on Days 1, 3, 6 (and Day 11 if unrelated donor). Treatment will be given in the hospital at UTMDACC. You will need to stay in the hospital for about 3 to 4 weeks. You must stay in the Houston area for about 100 days after the transplant. After that, you will need to return to Houston every three months for the first year, then every 6 months for 5 years for blood tests (1-2 tablespoons), urine tests, and CT scans. Bone marrow aspirations and biopsies will also be performed. Patients will be taken off study if the intolerable side effects occur. This is an investigational study. The FDA has approved the drugs used in this study. Their use together in this study is investigational. About 30 patients will take part in this study. All will be enrolled at UTMDACC.
Interventions
DRUGCampath-1H
3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
DRUGG-CSF
10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
DRUGGM-CSF
250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
DRUGBCNU
300 mg/m2 IV over 1 hour on day -6
DRUGStem Cell Transplant
Stem cell infusion on Day 0.
DRUGPreparative Regimen for Allogenic Stem Cell Transplantation
Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
DRUGCytarabine
200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
DRUGEtoposide
200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
DRUGMelphalan
140 mg/m2 IV on day -1.
DRUGCampath
15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
DRUGFludarabine
30 mg/m2 IV/day (days -6 to -4)
DRUGCyclophosphamide
750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
RADIATIONLow dose total body irradiation
Low dose total body irradiation of 2 Gy day 0.
Sponsors
Bayer
M.D. Anderson Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be less then 70 years old. * Patients must have chemosensitive disease, having undergone at least partial remission with less then 10% marrow involvement by gross pathologic examination if autologous transplantation is considered. * Newly diagnosed patients are eligible for autologous transplant. Patients in relapse would receive a non-myeloablative transplant if a sibling donor is available. Otherwise, patients would undergo autologous transplant if International Prognostic Index (IPI) is 0-1, or unrelated transplant if IPI is \> 1.
Exclusion criteria
* Criteria for exclusion are Human immunodeficiency virus (HIV) or Human T-lymphotropic virus (HTLV) seropositivity, pregnancy, cardiac ejection fraction by echo-cardiogram less than 40%, active central nervous system involvement, serum creatinine greater than 1.6 mg/dl or serum bilirubin greater than 1.5 mg/dl unless due to tumor, Absolute neutrophil count (ANC) less than 1,000/mm3 and platelets less than 100,000/mm3 unless due to tumor, performance status (ECOG scale) greater than 2, pulmonary function test- diffusing capacity of the Lung for Carbon Monoxide (DLCO) less than 40% of predicted, and severe concomitant medical or psychiatric illnesses.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participant Progression Free Survival at 2 Years | 2 years | Progression-free survival defined as the number of participants without evidence of progression or death after 2 years from stem cell transplant. |
Countries
United States
Participant flow
Recruitment details
Recruitment period: 3/11/2003 to 10/27/2009. All participants were registered at UT MD Anderson Cancer Center
Pre-assignment details
Eight patients of those twenty-seven registered failed to mobilize an adequate number of stem cells for an autologous transplant and were taken off the study.
Participants by arm
| Arm | Count |
|---|---|
| Campath-1H 3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0. | 27 |
| Total | 27 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Failed to Mobilize | 8 |
| Overall Study | Ineligible | 1 |
Baseline characteristics
| Characteristic | Campath-1H |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 27 Participants |
| Age Continuous | 44 years FULL_RANGE 0 |
| Region of Enrollment United States | 27 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 18 / 18 |
| serious Total, serious adverse events | 0 / 18 |
Outcome results
Primary
Participant Progression Free Survival at 2 Years
Progression-free survival defined as the number of participants without evidence of progression or death after 2 years from stem cell transplant.
Time frame: 2 years
Population: Analysis was per protocol. Nine participants were not eligible for treatment therefore were excluded from analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Campath-1H | Participant Progression Free Survival at 2 Years | 15 participants |